Neurocrine Biosciences (NBIX): Survey Shows Ingrezza To Be Restricted - Jefferies

Jefferies analyst, Biren Amin, reiterated his Buy rating on shares of Neurocrine Bio. (NASDAQ: NBIX) after an analyst sponsored payor survey found that the majority of payors (80%) plan to restrict Ingrezza to moderate-severe TD patients. It also revealed that approximately 44% expect to implement the AIMS score to determine TD severity and 65% will require an antipsychotic switching step edit.

Despite this feedback, the analyst believes consensus estimates for '17 and '18 appear achievable. There was no change to the price target of $66.

For an analyst ratings summary and ratings history on Neurocrine Bio. click here. For more ratings news on Neurocrine Bio. click here.

Shares of Neurocrine Bio. closed at $46.22 yesterday.

You May Also Be Interested In

• Cummins (CMI) PT Lowered to $675 at Jefferies
• DA Davidson Starts Comfort Systems USA (FIX) at Buy
• Mizuho Reiterates Outperform Rating on Broadcom Limited (AVGO) Into EPS